Press release
Microvascular Angina Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Yale University, Millennium Pharma, AstraZeneca, Sanofi
The Key Microvascular Angina Companies in the market include - NHS Greater Glasgow and Clyde, Yale University, Millennium Pharma, AstraZeneca, Sanofi, and others.DelveInsight's "Microvascular Angina Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Microvascular Angina, historical and forecasted epidemiology as well as the Microvascular Angina market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Microvascular Angina, offering comprehensive insights into the Microvascular Angina revenue trends, prevalence, and treatment landscape. The report delves into key Microvascular Angina statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Microvascular Angina therapies. Additionally, we cover the landscape of Microvascular Angina clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Microvascular Angina treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Microvascular Angina space.
To Know in detail about the Microvascular Angina market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Microvascular Angina Market Forecast [https://www.delveinsight.com/sample-request/microvascular-angina-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Microvascular Angina Market Report:
*
The Microvascular Angina market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
Key Microvascular Angina Companies: NHS Greater Glasgow and Clyde, Yale University, Millennium Pharma, AstraZeneca, Sanofi, and others
*
Key Microvascular Angina Therapies: Zibotentan, Ranolazine, Percutaneous Coronary Intervention (PCI), Rosuvastatin, clopidogrel, and others
*
The Microvascular Angina market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Microvascular Angina pipeline products will significantly revolutionize the Microvascular Angina market dynamics.
*
Among patients with angina symptoms and positive non-invasive ischemia tests but no obstructive coronary artery disease (CAD), the median prevalence of suspected MVA is approximately 43%, with reported ranges between 33% and 65%.
*
When using specialized diagnostic tools such as invasive coronary reactivity tests or coronary flow reserve measurements, the median prevalence of suspected MVA is about 28%, ranging from 13.5% to 46.5%.
*
In studies employing both ischemia testing and evidence of impaired microvascular function, the median prevalence of definitive MVA is around 30%, with a range of 19.7% to 60%.
Microvascular Angina Overview
Microvascular Angina (MVA) - also known as cardiac syndrome X - is a type of chest pain (angina) caused by abnormalities or dysfunction in the small coronary arteries (microvasculature) that supply blood to the heart muscle. Unlike classic angina, which is usually due to blockages in large coronary arteries, MVA occurs even when the larger arteries appear normal on angiograms.
Get a Free sample for the Microvascular Angina Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/microvascular-angina-market [https://www.delveinsight.com/report-store/microvascular-angina-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Microvascular Angina Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Microvascular Angina Epidemiology Segmentation:
The Microvascular Angina market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of Microvascular Angina
*
Prevalent Cases of Microvascular Angina by severity
*
Gender-specific Prevalence of Microvascular Angina
*
Diagnosed Cases of Episodic and Chronic Microvascular Angina
Download the report to understand which factors are driving Microvascular Angina epidemiology trends @ Microvascular Angina Epidemiology Forecast [https://www.delveinsight.com/sample-request/microvascular-angina-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Microvascular Angina Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Microvascular Angina market or expected to get launched during the study period. The analysis covers Microvascular Angina market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Microvascular Angina Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Microvascular Angina Therapies and Key Companies
*
Zibotentan: NHS Greater Glasgow and Clyde
*
Ranolazine: Yale University
*
Percutaneous Coronary Intervention (PCI): Millennium Pharma
*
Rosuvastatin: AstraZeneca
*
clopidogrel: Sanofi
Discover more about therapies set to grab major Microvascular Angina market share @ Microvascular Angina Treatment Landscape [https://www.delveinsight.com/sample-request/microvascular-angina-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Microvascular Angina Market Drivers
*
High Prevalence of Non-Obstructive Angina
*
Advancements in Diagnostic Techniques
*
Increased Awareness and Recognition
*
Emergence of Targeted Therapies
Microvascular Angina Market Barriers
*
Diagnostic Challenges
*
Limited Treatment Options
*
Underrepresentation in Clinical Trials
*
Healthcare Provider Awareness
Scope of the Microvascular Angina Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Microvascular Angina Companies: NHS Greater Glasgow and Clyde, Yale University, Millennium Pharma, AstraZeneca, Sanofi, and others
*
Key Microvascular Angina Therapies: Zibotentan, Ranolazine, Percutaneous Coronary Intervention (PCI), Rosuvastatin, clopidogrel, and others
*
Microvascular Angina Therapeutic Assessment: Microvascular Angina current marketed and Microvascular Angina emerging therapies
*
Microvascular Angina Market Dynamics: Microvascular Angina market drivers and Microvascular Angina market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Microvascular Angina Unmet Needs, KOL's views, Analyst's views, Microvascular Angina Market Access and Reimbursement
To know more about Microvascular Angina companies working in the treatment market, visit @ Microvascular Angina Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/microvascular-angina-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Microvascular Angina Market Report Introduction
2. Executive Summary for Microvascular Angina
3. SWOT analysis of Microvascular Angina
4. Microvascular Angina Patient Share (%) Overview at a Glance
5. Microvascular Angina Market Overview at a Glance
6. Microvascular Angina Disease Background and Overview
7. Microvascular Angina Epidemiology and Patient Population
8. Country-Specific Patient Population of Microvascular Angina
9. Microvascular Angina Current Treatment and Medical Practices
10. Microvascular Angina Unmet Needs
11. Microvascular Angina Emerging Therapies
12. Microvascular Angina Market Outlook
13. Country-Wise Microvascular Angina Market Analysis (2019-2032)
14. Microvascular Angina Market Access and Reimbursement of Therapies
15. Microvascular Angina Market Drivers
16. Microvascular Angina Market Barriers
17. Microvascular Angina Appendix
18. Microvascular Angina Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=microvascular-angina-market-predicted-to-see-upsurge-through-2032-highlights-delveinsight-yale-university-millennium-pharma-astrazeneca-sanofi]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Microvascular Angina Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Yale University, Millennium Pharma, AstraZeneca, Sanofi here
News-ID: 4043237 • Views: …
More Releases from ABNewswire

Pataskala Fence Company Adds New Service of Composite Deck Installation to Bette …
Pataskala, Ohio - October 8, 2025 - Pataskala Fence Company, a longtime provider of residential and commercial fencing services in central Ohio, today announced an expansion of its service offerings: the company will now provide composite deck installation in the Pataskala area and surrounding communities. As a qualified composite deck contractor [https://www.pataskalafencecompany.com/], Pataskala Fence Company promises to only use the highest quality material and labor for its Pataskala residents.
For over…

The Evolving Role of Nutrition Experts in Modern Health: Berry Street's Approach …
Image: https://www.abnewswire.com/upload/2025/10/82bfff216b391ff13171536dbd26c34c.jpg
In recent years, the role of nutrition experts has undergone a significant transformation. As health becomes increasingly intertwined with diet and lifestyle choices, we find ourselves navigating a complex landscape.
When it comes to individual wellness, understanding the nuances of professional guidance is essential. For example, many people wonder about the difference between a dietitian vs nutritionist for weight loss [https://www.berrystreet.co/blog/should-i-see-a-dietitian-or-nutritionist-to-lose-weight]. Knowing which professional to consult can help ensure the…

New product release: AIMI for Agentic AI (Tools Calling) Security
Chatterbox Labs [http://chatterbox.co/] are pleased to announce the availability of their new Agentic AI Security (tools calling) pillar, part of the AIMI product portfolio.
At Chatterbox Labs, we've been leading the way in AI security and safety testing for over a decade. We pioneered the automated testing of predictive AI models, and our generative AI security testing software is helping leading enterprises and foundation AI model builders to ensure that their…

Common Retirement Planning Mistakes to Avoid
When you start planning for retirement, it may seem like those years are way down the line, and you have plenty of time to prepare. But this type of thinking leaves you open to making amateur financial mistakes!
As you consider how you'll plan for your Golden Years, you don't want to outlive your savings, especially with the ever-lengthening lifespan trends you may get to enjoy! To prevent this problem from…
More Releases for Angina
Surging Prevalence Of Cardiovascular Diseases Propels Growth In The Angina Pecto …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Angina Pectoris Drugs Market Size By 2025?
The market size for angina pectoris drugs has experienced consistent growth in the past few years. The market is projected to expand from $12.32 billion in 2024 to $12.88 billion in 2025, representing a compound annual growth rate…
Angina (Angina Pectoris) Pipeline: 10+ Companies Transforming Chest Pain Managem …
The angina therapeutics pipeline is experiencing a renaissance, driven by pharmaceutical companies such as Abbott Laboratories, AstraZeneca, Bayer AG, and Bristol-Myers Squibb. With a focus on improving myocardial efficiency and reducing ischemic burden, emerging therapies-including metabolic modulators, nitric oxide donors, and gene therapies-aim to offer more effective symptom relief and reduce cardiovascular events. Innovations are targeting both stable and microvascular angina forms, addressing the significant unmet needs in chronic angina…
What's Driving the Angina Market 2025-2034: The Rising Prevalence of Coronary Ar …
What Are the Projections for the Size and Growth Rate of the Angina Market?
The scale of the angina market has seen robust growth in the previous years. The expansion is expected to continue, increasing from a value of $10.71 billion in 2024 to $11.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.4%. The surge in the past period can be credited to factors such as a…
Angina Pectoris - Drug Pipeline Landscape, 2022
Global Angina Pectoris Market report from Global Insight Services is the single authoritative source of intelligence on angina pectoris market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Angina Pectoris - Drug Pipeline Landscape, 2022
Angina also known as angina pectoris, is a type of chest pain or discomfort that occurs when a part of the heart doesn't get enough blood and oxygen, which is due to the spasm or obstruction of the arteries that supply the blood to the heart muscles. Angina is mainly of four types: stable angina, unstable angina, microvascular angina, and vasospastic or variant angina.
Angina is caused due to the built…
Angina Pectoris Drugs Market Set for Rapid Growth
Global Angina Pectoris Drugs Market: Overview
The demand within the global market for angina pectoris drugs has been rising on account of the focus given on treating medical conditions suffered by the geriatric population. The presence of a seamless industry for healthcare diagnostic and treatment has played a major role in market growth. Angina pectoris is a type of chest pain that is triggered due to reduced blood flow to…